We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
Altimmune plans to launch a global phase III MASH study for pemvidutide in 2H 2026.
ALT reported phase IIb data showing MASH resolution and fibrosis improvement through 48 weeks.
Altimmune expects top-line AUD study data in Q3 2026 and is advancing a phase II ALD study.
Altimmune (ALT - Free Report) , a late clinical-stage biotech, is focused on developing therapies for liver diseases. Its lead pipeline candidate, pemvidutide, is a balanced 1:1 glucagon/GLP-1 dual receptor agonist and has a differentiated mechanism of action with a “pipeline in a product” potential for the treatment of liver diseases. Altimmune is positioning itself as a differentiated player with the potential to compete in large commercial indications such as metabolic dysfunction-associated steatohepatitis ("MASH"), alcohol use disorder ("AUD") and alcohol-associated liver disease ("ALD").
Year to date, shares of Altimmune have lost 18.9% compared with the industry’s 6.5% decline.
Image Source: Zacks Investment Research
Strong Momentum in the Multi-Billion-Dollar MASH Market
An important catalyst supporting investor enthusiasm is Altimmune’s expanding opportunity in the MASH market. The disease represents a multi-billion-dollar commercial opportunity with limited approved treatment options. The recent data from the phase IIb IMPACT study evaluating pemvidutide in MASH patients demonstrated statistically significant MASH resolution without worsening of fibrosis at 24 weeks, sustained through 48 weeks. It also showed clear signs of reducing liver scarring by 48 weeks. Key markers of liver damage and inflammation continued to improve over time, showing steady progress with the added benefit of weight loss.
The candidate’s relatively simple dosing profile may also support better patient adherence compared with more complex injectable regimens.
Altimmune recently announced alignment with the FDA on key parameters for a late-stage MASH program and plans to initiate a global phase III registrational PERFORMA study in the second half of 2026. The study will evaluate pemvidutide in MASH patients with moderate-to-severe fibrosis, with 52-week data expected in 2029.
Beyond MASH, Altimmune is also evaluating pemvidutide in separate mid-stage studies for alcohol-related diseases like AUD and ALD. Top-line data from the mid-stage RECLAIM study evaluating pemvidutide for the treatment of patients with AUD is expected in the third quarter of 2026. Enrollment was completed ahead of schedule in November 2025.
Altimmune is also developing the candidate in the phase II RESTORE study in patients with ALD. Patient enrollment is expected to be completed by the third quarter of 2026.
The candidate holds Fast Track designations for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH.
ALT's Zacks Rank & Estimates
Altimmune currently carries a Zacks Rank #2 (Buy). Over the past 30 days, estimates for ALT’s 2026 and 2027 loss per share have narrowed from $1.00 to 69 cents and from $1.00 to 73 cents, respectively.
Over the past 60 days, estimates for Immunocore’s 2026 loss per share have narrowed from 97 cents to 16 cents. Over the same period, estimates for 2027 have improved from a loss of 39 cents to earnings of 11 cents per share. IMCR's shares have lost 13.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.10 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.47. INDV's shares have risen 4.4% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA's shares have gained 79.6% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
Key Takeaways
Altimmune (ALT - Free Report) , a late clinical-stage biotech, is focused on developing therapies for liver diseases. Its lead pipeline candidate, pemvidutide, is a balanced 1:1 glucagon/GLP-1 dual receptor agonist and has a differentiated mechanism of action with a “pipeline in a product” potential for the treatment of liver diseases. Altimmune is positioning itself as a differentiated player with the potential to compete in large commercial indications such as metabolic dysfunction-associated steatohepatitis ("MASH"), alcohol use disorder ("AUD") and alcohol-associated liver disease ("ALD").
Year to date, shares of Altimmune have lost 18.9% compared with the industry’s 6.5% decline.
Image Source: Zacks Investment Research
Strong Momentum in the Multi-Billion-Dollar MASH Market
An important catalyst supporting investor enthusiasm is Altimmune’s expanding opportunity in the MASH market. The disease represents a multi-billion-dollar commercial opportunity with limited approved treatment options. The recent data from the phase IIb IMPACT study evaluating pemvidutide in MASH patients demonstrated statistically significant MASH resolution without worsening of fibrosis at 24 weeks, sustained through 48 weeks. It also showed clear signs of reducing liver scarring by 48 weeks. Key markers of liver damage and inflammation continued to improve over time, showing steady progress with the added benefit of weight loss.
The candidate’s relatively simple dosing profile may also support better patient adherence compared with more complex injectable regimens.
Altimmune recently announced alignment with the FDA on key parameters for a late-stage MASH program and plans to initiate a global phase III registrational PERFORMA study in the second half of 2026. The study will evaluate pemvidutide in MASH patients with moderate-to-severe fibrosis, with 52-week data expected in 2029.
Altimmune, Inc. Price and Consensus
Altimmune, Inc. price-consensus-chart | Altimmune, Inc. Quote
Pemvidutide’s Expansion Beyond MASH
Beyond MASH, Altimmune is also evaluating pemvidutide in separate mid-stage studies for alcohol-related diseases like AUD and ALD. Top-line data from the mid-stage RECLAIM study evaluating pemvidutide for the treatment of patients with AUD is expected in the third quarter of 2026. Enrollment was completed ahead of schedule in November 2025.
Altimmune is also developing the candidate in the phase II RESTORE study in patients with ALD. Patient enrollment is expected to be completed by the third quarter of 2026.
The candidate holds Fast Track designations for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH.
ALT's Zacks Rank & Estimates
Altimmune currently carries a Zacks Rank #2 (Buy). Over the past 30 days, estimates for ALT’s 2026 and 2027 loss per share have narrowed from $1.00 to 69 cents and from $1.00 to 73 cents, respectively.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Immunocore (IMCR - Free Report) , Indivior Pharmaceuticals (INDV - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Immunocore’s 2026 loss per share have narrowed from 97 cents to 16 cents. Over the same period, estimates for 2027 have improved from a loss of 39 cents to earnings of 11 cents per share. IMCR's shares have lost 13.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.10 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.47. INDV's shares have risen 4.4% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA's shares have gained 79.6% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.